Literature DB >> 11122695

Genetics of familial combined hyperlipidemia.

P Pajukanta1, K V Porkka.   

Abstract

Complex disorders are caused by several environmental factors that interact with multiple genes. These diseases are common at the population level and constitute a major health problem in Western societies. Familial combined hyperlipidemia (FCHL) is characterized by elevated levels of serum total cholesterol, triglycerides, or both. This disorder is estimated to be common in Western populations with a prevalence of 1% to 2%. In addition, 14% of patients with premature coronary heart disease (CHD) have FCHL, making this disorder one of the most common genetic dyslipidemias underlying premature CHD. Both genetic and environmental factors are suggested to affect the complex FCHL phenotype, but no specific susceptibility genes to FCHL have been identified. It is hoped that further analysis of the first FCHL locus and other new loci obtained in genome-wide scans will guide us to genes predisposing to this complex disorder.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11122695     DOI: 10.1007/s11883-999-0053-3

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.967


  53 in total

1.  Sequential tests for the detection of linkage.

Authors:  N E MORTON
Journal:  Am J Hum Genet       Date:  1955-09       Impact factor: 11.025

2.  The future of genetic studies of complex human diseases.

Authors:  N Risch; K Merikangas
Journal:  Science       Date:  1996-09-13       Impact factor: 47.728

3.  Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia.

Authors:  A Chait; J J Albers; J D Brunzell
Journal:  Eur J Clin Invest       Date:  1980-02       Impact factor: 4.686

4.  Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes.

Authors:  G M Dallinga-Thie; M van Linde-Sibenius Trip; J I Rotter; R M Cantor; X Bu; A J Lusis; T W de Bruin
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

5.  No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in Finnish families.

Authors:  P Pajukanta; K V Porkka; M Antikainen; M R Taskinen; M Perola; S Murtomäki-Repo; S Ehnholm; I Nuotio; L Suurinkeroinen; A T Lahdenkari; A C Syvänen; J S Viikari; C Ehnholm; L Peltonen
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-05       Impact factor: 8.311

6.  Lack of association of the apolipoprotein A-I-C-III-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects.

Authors:  M Marcil; B Boucher; E Gagné; J Davignon; M Hayden; J Genest
Journal:  J Lipid Res       Date:  1996-02       Impact factor: 5.922

7.  A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia.

Authors:  S H Juo; S J Bredie; L A Kiemeney; P N Demacker; A F Stalenhoef
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

8.  A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia.

Authors:  P W Reymer; B E Groenemeyer; E Gagné; L Miao; E E Appelman; J C Seidel; D Kromhout; S M Bijvoet; K van de Oever; T Bruin
Journal:  Hum Mol Genet       Date:  1995-09       Impact factor: 6.150

9.  Linkage of atherogenic lipoprotein phenotype to the low density lipoprotein receptor locus on the short arm of chromosome 19.

Authors:  P M Nishina; J P Johnson; J K Naggert; R M Krauss
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

10.  Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia.

Authors:  J D Brunzell; J J Albers; A Chait; S M Grundy; E Groszek; G B McDonald
Journal:  J Lipid Res       Date:  1983-02       Impact factor: 5.922

View more
  1 in total

Review 1.  Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century.

Authors:  T A Jacobson
Journal:  Curr Atheroscler Rep       Date:  2001-09       Impact factor: 5.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.